FDA
-
-
-
-
-
-
-
Amneal reports positive interim results for Parkinson's drug CREXONT
-
-
-
-
-
-
-
Amneal agrees to acquire Kashiv BioSciences for $750 million
-
-
-
-
-
-
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
-
-
-
-
-
-
Amneal reports positive interim results for Parkinson's drug CREXONT
-
-
-
-
-
-
-
Amneal Receives U.S. FDA Approval for Iohexol Injection
-
-
-
-
-
-
-
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
-
-
-
-
-
-
-
Amneal Reports Second Quarter 2025 Financial Results
-
325,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

